Syndax Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 3 Sell calls were followed by a 7% average decline over the next quarter.
- Recent price momentum is -52.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 21.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 96.0% | Better than 98% |
| Operating margin | -158.4% | Better than 6% |
| Net margin | -165.6% | Better than 6% |
| Return on equity | -161.8% | Better than 4% |
| Return on invested capital | -148.9% | Better than 1% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -55.6% | Better than 4% |
| 6-month return | -56.3% | Better than 5% |
| 12-month return (ex latest month) | -22.2% | Better than 13% |
| Distance below 52-week high | 65.9% | Better than 8% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.4x | Better than 83% |
| Debt to assets | 0.3% | Better than 97% |
| Interest coverage | -7.4x | Better than 14% |
| Free cash flow / net income | 116.4% | Better than 49% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 332.0% | Better than 98% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.13
- Open
- 9.07
- Day range
- 8.69 - 9.27
- Avg price
- 8.88
- Volume
- 2.18M
- Turnover
- 19.38M
- Turnover ratei
- 2.69%
- Volume ratioi
- 0.73
- Amplitudei
- 6.35%
- 52-week rangei
- 8.41 - 25.59
Valuation
- P/Ei
- -2.65
- P/E (TTM)i
- -3.68
- P/Bi
- -45.65
- EPSi
- -3.29
- Book value / shi
- -0.19
- Net profit
- -296.19M
- Net assets
- -17.20M
Share structure
- Market cap
- 785.05M
- Float capi
- 707.10M
- Shares out
- 90.03M
- Float sharesi
- 81.09M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-03-03
65.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-29.26M net over the window
Short interest
- Shares short
- 18.92M
- % of floati
- 21.19%
- Days to coveri
- 6.41
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
Syndax Pharmaceuticals last traded at 8.72. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Syndax Pharmaceuticals's market cap?
About 785.05M.
What is the P/E ratio of Syndax Pharmaceuticals?
The trailing twelve-month P/E is -3.68, below its own 5-year average of 5.07 — in the middle of its historical range (65.95% percentile). See the Valuation tab for the full history.
Does Syndax Pharmaceuticals pay a dividend?
Syndax Pharmaceuticals does not currently pay a regular dividend.
Is Syndax Pharmaceuticals a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 37.67, which implies 332.0% upside from the current price. This is not investment advice.
What is Syndax Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Syndax Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Syndax Pharmaceuticals discussion 0 comments